Dysfunctional high-density lipoprotein predicts survival, renal recovery and the need for kidney replacement therapy in acute kidney injury

功能异常的高密度脂蛋白可预测急性肾损伤患者的生存率、肾功能恢复情况以及是否需要肾脏替代治疗。

阅读:2

Abstract

INTRODUCTION: There is growing evidence that oxidative stress contributes not only to the pathophysiology of atherosclerosis but also to acute kidney injury (AKI). This study investigated the prognostic value of nHDL(ox) (normalized high-density lipoprotein with reduced antioxidant function) in hospitalized patients with AKI. METHODS: nHDL(ox) was measured within 48 hours of AKI diagnosis. We assessed its performance in predicting the following primary endpoints: in-hospital all-cause mortality, need for kidney replacement therapy (KRT), and restoration of kidney function before discharge. Secondary endpoints included clinical markers of severe disease course: intensive care treatment, ventilatory support, and vasopressor requirement. RESULTS: Among 132 participants, 16.7% died in the hospital, 36.4% required KRT, and 31.1% had no restoration of kidney function. For all primary endpoints, nHDL(ox) levels were significantly higher in non-survivors (2.00 vs. 1.26; +58.7%; p = 0.009), in patients requiring KRT (1.66 vs. 1.23; +34.9%; p = 0.002), and in those without renal recovery (1.71 vs. 1.23; +39.0%; p = 0.001). nHDL(ox) was independently associated with death, KRT, and lack of renal recovery, with odds ratios for a twofold increase (95% CI) of 1.88 (1.19-2.98), 1.78 (1.17-2.69), and 2.09 (1.34-3.26), respectively. Predictive performance was moderate, with AUC-ROC values (95% CI) of 0.68 (0.54-0.81), 0.66 (0.56-0.76), and 0.67 (0.57-0.78). No differences were observed across secondary endpoints. CONCLUSIONS: Impaired antioxidant HDL function is closely associated with clinically relevant AKI outcomes. nHDL(ox), therefore, represents a significant risk factor in both cardiovascular and kidney disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。